نتایج جستجو برای: brafv600e
تعداد نتایج: 835 فیلتر نتایج به سال:
The back cover image describes a DCNN model based on ultrasound images to predict the BRAFV600E mutation in thyroid nodules which achieved encouraging predictive performance test sets from four hospitals (AUC 0.84–0.93). This might provide non-invasive and convenient method for predicting assist clinicians select more appropriate management patients with or cancer.
Melanoma is the most lethal form of skin cancer. Until 2011, the favored therapy was chemotherapy despite their low efficiency. Spectacular progresses were made in melanoma treatment using targeted therapies anti-BRAFV600E / anti-MEK and immunotherapy antiCTLA-4 / anti PD-1. Unfortunately, more than 50% of patients present intrinsic or acquire resistance and are in treatment failure. So identif...
Current knowledge on biomarkers (BRAFV600E/RAS mutations) is mainly based metastatic colorectal cancer (mCRC) patients with proficient mismatch repair (pMMR) tumors. It uncertain whether these have the same implications in deficient (dMMR) mCRC patients. Our aim to provide insight value of Lynch syndrome, BRAFV600E and RAS mutation status treatment regimens survival dMMR treated outside clinica...
Abstract Background NHS England’s reorganization of genomic testing has provided an opportunity to explore molecular as part thyroid nodule diagnostics and the routine postoperative histology. Aim Routine in service not previously been explored. This study aims evaluate whether (1) there is sufficient material perform this on FNAC cytologically indeterminate nodules (2) what yield from (3) post...
The synergistic effect of dual inhibition serine/threonine protein kinases that are involved in the same signalling pathway diseases can exert superior biological benefits for treatment these diseases. In present work, a new series (imidazol-5-yl)pyrimidine was designed and synthesized as inhibitors BRAFV600E p38? which considered key regulators mitogen-activated kinase (MAPK) pathway. target c...
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there is a pressing need to identify the major mechanisms of intrinsic and adaptive resistance and develop drug combinations that target these resistance mechanisms. In a combinatorial drug screen on a pa...
Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective treatments. Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models of thyroid cancer, however, neither drug induces notable apoptosis. Here we report that the SRC-inhibitor dasatinib further sensitizes BRAFV600E-positive thyroid cancer cells to the BRAFV600E-inhibitor PLX4720. Combine...
Langerhans cell histiocytosis (LCH) is a myeloproliferative disorder characterized by lesions composed of pathological CD207(+) dendritic cells with an inflammatory infiltrate. BRAFV600E remains the only recurrent mutation reported in LCH. In order to evaluate the spectrum of somatic mutations in LCH, whole exome sequencing was performed on matched LCH and normal tissue samples obtained from 41...
The BRAF(V600E) inhibitor PLX4032 (Vemurafenib) is an FDA-approved new drug for the treatment of metastatic melanomas, which specifically inhibits the RAS/MEK/ERK signaling pathway to control cell proliferation and adhesion. However, no study has been carried out to investigate the role of intracellular oxidative balance in PLX4032-induced tumor growth inhibition. Herein, for the first time, su...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید